To specifically validate PHGDH as a therapeutically actionable target in MYC-driven MB, we assessed its protein expression in a large representative cohort of primary medulloblastomas (n = 183) and normal cerebellar controls (n = 9) (Supplementary Table 3). The gene discussed is MYC; the disease is medulloblastoma.